Revisiting live attenuated influenza vaccine efficacy among children in developing countries

Sumedha Bagga1, Anand Krishnan2, Lalit Dar1

  • 1Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.

Vaccine
|January 5, 2023
PubMed

Insights

Live attenuated influenza vaccines (LAIVs) show promise for children in developing nations. However, their efficacy varies, necessitating further research into factors like viral strain selection for optimal pediatric influenza protection.

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Global health

Background:

  • Seasonal influenza causes significant global pediatric mortality and morbidity.
  • Live attenuated influenza vaccines (LAIVs) offer advantages like intranasal administration and higher manufacturing yields compared to inactivated influenza vaccines (IIVs).
  • LAIVs are particularly attractive for children in developing countries due to disease burden and logistical benefits.

Purpose of the Study:

  • To summarize recent pediatric studies on LAIV efficacy in developing countries.
  • To analyze factors contributing to the varied efficacy of LAIVs in diverse settings.
  • To inform strategies for improving LAIV utility in resource-poor regions.

Main Methods:

  • Review of recent randomized controlled trials (RCTs) evaluating LAIV efficacy in pediatric populations.
  • Analysis of vaccine efficacy data from studies conducted in Bangladesh, Senegal, and India.
  • Examination of historical data and recommendations from the CDC Advisory Committee on Immunization Practices (ACIP).

Main Results:

  • Conflicting LAIV efficacy results were reported in trials in Bangladesh (41%) and Senegal (0.0%).
  • Previous Ann Arbor-based LAIV showed higher efficacy than IIV before 2013, but faced challenges with influenza A(H1N1)pdm09 strains.
  • A recent Indian RCT indicated lower LAIV efficacy compared to IIV in Year 1, with comparable efficacy in Year 2.

Conclusions:

  • The efficacy of LAIVs in developing countries is variable and requires deeper mechanistic understanding.
  • Assessing replicative fitness alongside antigenicity is crucial for selecting annual influenza A(H1N1)pdm09 components for Russian-backbone LAIVs.
  • Optimizing LAIVs based on these factors could enhance their widespread use in resource-limited settings.